Go to the list of all blogs
John Y White's Avatar
published in Blogs
Jul 31, 2026
Why Is AXT, Inc. (AXTI) Stock Up +24.76% Today?

Why Is AXT, Inc. (AXTI) Stock Up +24.76% Today?

Key Takeaways

  • AXTI shares surged 24.76% in Friday's trading session, reaching $58.56 after closing at $46.94 the previous day, extending a powerful two-day rally.
  • The primary catalyst was a blowout Q2 2026 earnings report released after Thursday's close, in which AXT delivered record revenue of $47.6 million and swung to a non-GAAP profit of $0.19 per share, crushing consensus estimates.
  • Q3 guidance far exceeded Wall Street expectations, with management forecasting EPS of $0.30–$0.32 on revenue of approximately $66 million, compared to analyst estimates of $0.10 and $38.7 million respectively.
  • Record indium phosphide (InP) revenue of $30.7 million, driven by surging demand for AI data center optical connectivity, underscored the company's strategic position in the semiconductor substrate supply chain.
  • Long-term supply agreements with Lumentum, Coherent, and Casela — along with a backlog exceeding $100 million — provided additional confidence in AXT's multi-year growth trajectory.
  • Traders are now watching for further updates on export permit timelines, capacity expansion milestones, and the planned Hong Kong listing of subsidiary Tongmei.

Opening Summary

AXTI — AXT, Inc., a Fremont, California-based global supplier of compound and single-element semiconductor substrates — saw its shares rocket higher by 24.76% on Friday, continuing a powerful rally sparked by the company's second-quarter 2026 earnings release. After closing Thursday's regular session at $46.94 — already up nearly 27% on the day — the stock extended its gains in Friday trading to reach $58.56. The dramatic move reflects overwhelming investor enthusiasm following quarterly results that not only shattered expectations but also included forward guidance that signals a fundamental inflection point for the business.

Earnings Blowout: Q2 Results Crush Consensus

AXT reported second-quarter revenue of $47.6 million, a record for the company, representing a 164% surge from the $18.0 million reported in the same quarter a year ago and a 77% sequential increase from Q1 2026. The result demolished the Wall Street consensus estimate of approximately $34.1 million. Non-GAAP earnings per share came in at $0.19, an extraordinary outperformance compared to the $0.07 consensus — a beat of roughly 171% — and a dramatic turnaround from a loss of $0.15 per share in the year-ago period.

The standout performer was indium phosphide (InP), which generated record quarterly revenue of $30.7 million, driven primarily by demand for data center optical connectivity applications. Non-GAAP gross margin expanded sharply to 45.0%, up from 29.9% in the prior quarter and just 8.2% a year ago, reflecting higher volumes and a favorable product mix as the company scaled production. CEO Morris Young declared that AXT has reached "an inflection point," crediting strong customer demand and improved manufacturing productivity for a "step-function increase" in revenue.

Blockbuster Guidance Signals Sustained Momentum

If the Q2 results ignited the rally, the third-quarter guidance poured fuel on the fire. AXT projected Q3 non-GAAP EPS of $0.30 to $0.32 — triple the $0.10 analyst consensus — on revenue of approximately $66 million, nearly 70% above the $38.7 million Street estimate. Management noted that the $66 million figure represents revenue for which the company already holds export permits or does not require them, providing a high degree of confidence. Executives further indicated potential for "significant upside" should additional export permits be granted for other orders already backed by inventory.

The guidance reflects not just a one-time surge but what management characterized as a new, structurally higher revenue run-rate, underpinned by accelerating deployment of optical connectivity as hyperscale data center operators migrate to higher-speed transceiver modules.

Strategic Supply Deals Lock In Long-Term Demand

Adding to the bullish narrative, AXT has secured a series of high-profile, multi-year supply agreements that bolster revenue visibility well into 2027 and beyond. On July 29, the company announced a long-term agreement with LITE — Lumentum Operations — to supply indium phosphide wafer substrates with reserved production capacity in exchange for prepayments. This followed earlier deals with COHR — Coherent Corp., which agreed to a $25.4 million prepayment — and Casela Technologies, which provided $22.3 million in upfront cash to secure capacity. Combined with an InP backlog that management described as "well over $100 million" and still growing, AXT's demand pipeline extends far beyond its current production capability.

Market Context and Trading Activity

Friday's surge occurred on exceptionally heavy volume, continuing the pattern from Thursday when more than 8.7 million shares changed hands versus a daily average of roughly 10 million. The move extended AXT's extraordinary year-to-date performance; even before this week's earnings-driven breakout, the stock had already rallied more than 150% in 2026, fueled by investor conviction that AI infrastructure spending would directly benefit upstream semiconductor material suppliers.

The broader semiconductor sector traded positively on Friday, but AXT's gains far outpaced both the SMH semiconductor ETF and the SOXX iShares Semiconductor ETF, underscoring the stock-specific nature of the catalyst. The rally pushed shares decisively above prior near-term resistance levels and through the psychologically important $50 threshold, though the stock remains well below its 52-week high of $143.16.

What Comes Next for AXTI

AXT enters the second half of 2026 with enormous tailwinds but also notable uncertainties. The company is racing to expand its indium phosphide production capacity, targeting quarterly capacity of roughly $60 million by year-end 2026 and approximately $130 million by end of 2027. Execution on these expansion plans will be critical, as demand continues to outstrip supply.

Export permit dynamics remain a key risk factor. A significant portion of AXT's revenue flows through its China-based subsidiary, and U.S.-China technology export controls introduce ongoing regulatory uncertainty. The planned shift of subsidiary Tongmei's IPO from Shanghai's STAR Market to the Hong Kong Exchange — a process expected to take approximately one year — adds another layer of complexity. Additionally, heavy insider selling in recent months, including by CEO Morris Young, may raise questions about valuation even as the fundamental story improves dramatically. Analyst opinions remain divided, with price targets ranging from $52 to $125, reflecting the wide dispersion of views on the durability of AXT's growth trajectory.

Trending AI Robots

For investors seeking systematic, data-driven approaches to navigating volatile markets, Tickeron's Trending AI Robots page offers a curated selection of top-performing AI trading bots. Tickeron provides hundreds of AI-powered trading bots spanning thousands of tickers, but only those demonstrating the strongest performance under current market conditions are featured in this dynamic, regularly updated section. Bots vary by trading strategy, timeframe, performance metrics, and the symbols they trade, allowing users to identify approaches aligned with their own investment style. Explore the Trending AI Robots page to discover which automated strategies are currently leading the pack.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: AXTI

Contributor

John Y White's AvatarJohn Y White|Beginner

AXTI in upward trend: price rose above 50-day moving average on August 06, 2026

AXTI moved above its 50-day moving average on August 06, 2026 date and that indicates a change from a downward trend to an upward trend. In of 50 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 30, 2026. You may want to consider a long position or call options on AXTI as a result. In of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for AXTI just turned positive on July 21, 2026. Looking at past instances where AXTI's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where AXTI advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for AXTI moved out of overbought territory on August 10, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where AXTI declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

AXTI broke above its upper Bollinger Band on August 07, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for AXTI entered a downward trend on August 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. AXTI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 63, placing this stock slightly worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.814) is normal, around the industry mean (8.640). AXTI's P/E Ratio (2617.333) is considerably higher than the industry average of (168.044). AXTI's Projected Growth (PEG Ratio) (0.000) is very low in comparison to the industry average of (1.601). AXTI has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.006). P/S Ratio (32.468) is also within normal values, averaging (37.998).

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 65.37B. The market cap for tickers in the group ranges from 555.66K to 689.17B. ASML holds the highest valuation in this group at 689.17B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 6%. For the same Industry, the average monthly price growth was 5%, and the average quarterly price growth was 46%. AEHR experienced the highest price growth at 31%, while SMTK experienced the biggest fall at -23%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -53%. For the same stocks of the Industry, the average monthly volume growth was -20% and the average quarterly volume growth was -62%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 33
Price Growth Rating: 45
SMR Rating: 74
Profit Risk Rating: 62
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
AXTI
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a manufactures of high-performance compound semiconductor substrates

Industry ElectronicProductionEquipment

Profile
Details
Industry
Electronic Production Equipment
Address
4281 Technology Drive
Phone
+1 510 438-4700
Employees
1075
Web
http://www.axt.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.